Valuation: Verde Science, Inc.

Market Cap 148K 132K 122K 110K 208K 13.96M 211K 1.46M 574K 7.34M 555K 544K 23.39M P/E 2013
-9.91x
P/E 2014 -0.23x
Enterprise Value 407K 363K 336K 304K 572K 38.39M 579K 4.02M 1.58M 20.18M 1.53M 1.49M 64.31M EV / Sales 2013
-
EV / Sales 2014 -
Free-Float
90.01%
Yield 2013 *
-
Yield 2014 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0.07
Manager TitleAgeSince
Chief Executive Officer 61 2012-06-13
Director TitleAgeSince
Chairman 61 2012-06-13
Director/Board Member 63 2014-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 23
-0.21%-4.43%+44.40%+74.13% 66.34B
+0.82%+5.41%+8.05%+73.53% 54.82B
-0.22%+6.53%+11.68%+87.32% 52.92B
+3.28%+5.58%+26.51%+50.05% 44.09B
+0.51%+9.95%+22.40%+133.92% 43.72B
-1.15%+0.39%+263.21%+594.60% 42.13B
+0.10%+9.90%+16.11%+59.33% 33.96B
-6.32%-5.14%+28.81%-0.02% 26.17B
+0.69%+5.60%+36.60%+26.94% 23.37B
Average -0.28%+4.27%+50.86%+122.20% 38.75B
Weighted average by Cap. -0.04%+4.54%+50.06%+127.29%

Financials

2013 2014
Net sales - -
Net income -798K -711K -658K -596K -1.12M -75.32M -1.14M -7.89M -3.1M -39.59M -2.99M -2.93M -126M -2.61M -2.33M -2.16M -1.95M -3.67M -247M -3.72M -25.84M -10.14M -130M -9.8M -9.6M -413M
Net Debt 252K 224K 208K 188K 354K 23.74M 358K 2.49M 976K 12.48M 944K 924K 39.77M 259K 231K 214K 193K 364K 24.43M 368K 2.56M 1M 12.84M 971K 951K 40.92M
Logo Verde Science, Inc.
Verde Science, Inc. is a pharmaceutical research and development company. The Company is engaged in medical science consulting business. The Company is focused on the discovery of drugs and treatment modalities, as well as diagnostic devices and pharmaceutical delivery systems for the treatment of diseases and medical issues. The Company is focused on developing medicinal formulations from cannabinoids and tetrahydrocannabinol (THC) compounds for the treatment of various issues, such as migraines, glaucoma, loss of appetite from cancer therapies, and other medical issues. The Company is focused on launching its THC Pharmaceutical Development Program by executing a research program, which involves developing formulations preparing protocols for clinical trials.
Employees
1
  1. Stock Market
  2. Stocks
  3. VRCI Stock